CTRI/2022/06/043262尚未招募未知
An Observational Study on Prevalence of Diseases w.s.r.to Deha Prakriti and Zodiac Sign (Janma Rashi)of Patient.
Dr Deepti Parashar0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •patients willing to provide necessary data.
- •patients who exactly know their date, place & time of birth.
- •patients of chronic and already diagnosed disorders.
- •patients who understand the need of survey and give written consent.
排除标准
- •1.Patients not willing to provide necessary data.
- •2.Patients who do not exactly know their date, place & time of birth.
- •3.Patients of acute and undiagnosed disorders.
- •4.Patients who do not understand the need of survey and do not give written consent.
研究者
相似试验
尚未招募
不适用
Study On The Profile And Vision Related Quality Of Life In Ocular And Orbital Injuries Due To Blunt Trauma In A Tertiary Care CentreCTRI/2019/11/021846Dr Megha Nair
招募中
不适用
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR)Mutation Status in Non-Small Cell Lung Cancer (NSCLC) in India.CTRI/2013/10/004077Roche Products India Pvt Ltd250
尚未招募
Unknown
A Study at Sawai Man Singh Medical College and Attached Hospitals, Jaipur to Find Out the Number of Patients Having Reduced Heart Rate in Lying Down Position, Reduced Blood Pressure in Lying Down Position and Fall in Blood Pressure in Sitting Position Among Patients of Spine InjuryCTRI/2024/04/066465SMS Medical College Jaipur
已完成
不适用
Epidemiological Study to Evaluate the Prevalence and Progression of Diabetic Macular Ischemia in Patients with Diabetic Retinopathy Treated with Panretinal PhotocoagulatioJPRN-UMIN000042801Boehringer Ingelheim International GmbH539
招募中
不适用
Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-upColorectal Cancer Stage IIColorectal Cancer Stage IIIDRKS00025104BioNTech SE1,500